



**Supplementary Figure 1 Kaplan-Meier analysis for overall survival according to high versus low ratio of CD68+ cells between tumor center and adjacent non-tumor mucosa.**

**Supplementary Table 1 The estimated probability of outcomes for stage I-III and stage IV colorectal cancer patients in Kaplan-Meier analysis**

		Stage I-III	Stage IV
Overall survival	1 year	93.2% (85.7%-100.0%) <sup>2</sup>	87.2% (78.3%-96.1%)
	3 years	62.6% (47.7%-77.5%)	51.9% (38.3%-65.5%)
	5 years	34.8% (17.0%-52.7%)	31.3% (17.9%-44.8%)
Disease-free survival	1 year	50.0% (35.2%-64.8%)	35.4% (22.7%-48.2%)
	3 years	17.6% (5.8%-29.3%)	11.4% (2.7%-20.1%)
	5 years	Not applicable <sup>1</sup>	7.0% (0%-14.8%)
Recurrence-free proportion	1 year	50.0% (35.2%-64.8%)	37.0% (23.9%-50.2%)
	3 years	17.6% (5.8%-29.3%)	11.9% (2.9%-21.0%)
	5 years	Not applicable <sup>1</sup>	7.3% (0%-15.5%)

<sup>1</sup>There were no complete observations after 5 years.

<sup>2</sup>Estimated probability of outcomes (95%CI).

**Supplementary Table 2 Spearman correlation between distance from tumor margin to adjacent non-tumor mucosa and macrophages in adjacent non-tumor mucosa of colorectal cancer patients stages I-III and IV**

	Stage I-III	Stage IV
--	-------------	----------

CD163 NM	0.18	0.13
CD206NM	-0.41 <sup>a</sup>	-0.04
CD68 NM	0.09	0.12
CD80 NM	0.21	0.08

<sup>a</sup> $P < 0.05$ .

**Supplementary Table 3 Spearman correlation between macrophages in adjacent non-tumor mucosa and in tumor center in colorectal cancer patient stage I-III and IV**

	Stages I-III			Stage IV		
	CD163	CD80	CD206	CD163	CD80	CD206
Adjacent non-tumor mucosa						
CD68	0.39 <sup>a</sup>	0.34 <sup>a</sup>	-0.20	0.69 <sup>a</sup>	0.32 <sup>a</sup>	-0.21
CD163		-0.04	-0.17		0.24	-0.20
CD80			-0.08			-0.27
Tumor center						
CD68	0.48 <sup>a</sup>	0.26	0.36 <sup>a</sup>	0.38 <sup>a</sup>	0.22	0.17
CD163		0.16	0.11		0.35 <sup>a</sup>	0.09
CD80			0.05			0.04

<sup>a</sup> $P < 0.05$ .

**Supplementary Table 4 Hazard ratios for disease-free survival between high vs. low cell density of macrophages in colorectal cancer patients' stage I-III versus IV**

	Stages I-III		Stage IV	
	<i>n</i> (%)	HR (95%CI), <i>P</i> value	<i>n</i> (%)	HR (95%CI), <i>P</i> value
CD163 NM	33 (75.0)	1.16 (0.54-2.52), <i>P</i> = 0.704	40 (74.1)	0.49 (0.25-0.95), <i>P</i> = 0.034
CD163 TC	31 (73.8)	1.06 (0.51-2.21), <i>P</i> = 0.871	40 (75.5)	1.31 (0.68-2.56), <i>P</i> = 0.420
CD163 TC/NM	21 (50.0)	0.88 (0.45-1.72), <i>P</i> = 0.709	26 (50.0)	1.03 (0.57-1.86), <i>P</i> = 0.917
CD206 NM	32 (74.4)	1.14 (0.53-2.42), <i>P</i> = 0.740	39 (75.0)	0.89 (0.46-1.72), <i>P</i> = 0.720
CD206 TC	32 (76.2)	0.78 (0.36-1.68), <i>P</i> = 0.529	40 (74.1)	0.94 (0.50-1.76), <i>P</i> = 0.847
CD206 TC/NM	21 (50.0)	1.26 (0.65-2.42), <i>P</i> = 0.497	25 (49.0)	1.04 (0.58-1.88), <i>P</i> = 0.890
CD68 NM	33 (75.0)	0.70 (0.34-1.41), <i>P</i> = 0.318	40 (74.1)	0.89 (0.47-1.69), <i>P</i> = 0.714

CD68 TC	31 (75.6)	0.79 (0.38-1.65), <i>P</i> = 0.531	40 (75.5)	0.80 (0.42-1.52), <i>P</i> = 0.487
CD68 TC/NM	20 (48.8)	0.73 (0.37-1.42), <i>P</i> = 0.357	26 (50.0)	0.65 (0.36-1.18), <i>P</i> = 0.158
CD80 NM	31 (73.8)	0.56 (0.26-1.17), <i>P</i> = 0.121	39 (75.0)	0.62 (0.32-1.21), <i>P</i> = 0.162
CD80 TC	30 (73.2)	1.13 (0.54-2.36), <i>P</i> = 0.744	39 (75.0)	0.81 (0.42-1.54), <i>P</i> = 0.515
CD80 TC/NM	20 (48.8)	1.21 (0.62-2.37), <i>P</i> = 0.574	24 (49.0)	0.92 (0.50-1.68), <i>P</i> = 0.777

Densities of macrophages (mm<sup>2</sup>) were converted into percentiles and then categorized into low (0-24 percentile) and high (25-100 percentile). Ratio of tumor center/NM was calculated by dividing the densities of macrophages in tumor center by their densities in NM. The median values of these ratios were used to classify the samples into 'high' and 'low' groups. Hazard ratios show the relative risk compared with 1.00 for low groups.

**Supplementary Table 5 Hazard ratios for time to recurrence between high vs low cell density of macrophages in colorectal cancer patients' stage I-III versus IV**

	Stages I-III		Stage IV	
	<i>n</i> (%)	HR (95%CI), <i>P</i> value	<i>n</i> (%)	HR (95%CI), <i>P</i> value
CD163 NM	33 (75.0)	1.16 (0.54-2.52), <i>P</i> = 0.704	40 (74.1)	0.50 (0.25-0.99), <i>P</i> = 0.047
CD163 TC	31 (73.8)	1.06 (0.51-2.21), <i>P</i> = 0.871	40 (75.5)	1.25 (0.64-2.43), <i>P</i> = 0.521
CD163 TC/NM	21 (50.0)	0.88 (0.45-1.72), <i>P</i> = 0.709	26 (50.0)	1.04 (0.57-1.90), <i>P</i> = 0.895
CD206_NM	32 (74.4)	1.14 (0.53-2.42), <i>P</i> = 0.740	39 (75.0)	0.83 (0.43-1.63), <i>P</i> = 0.591
CD206_TC	32 (76.2)	0.78 (0.36-1.68), <i>P</i> = 0.529	40 (74.1)	0.99 (0.52-1.89), <i>P</i> = 0.972
CD206 TC/NM	21 (50.0)	1.26 (0.65-2.42), <i>P</i> = 0.497	25 (49.0)	1.15 (0.63-2.10), <i>P</i> = 0.646
CD68 NM	33 (75.0)	0.70 (0.34-1.41), <i>P</i> = 0.318	40 (74.1)	0.74 (0.38-1.44), <i>P</i> = 0.369
CD68 TC	31 (75.6)	0.79 (0.38-1.65), <i>P</i> = 0.531	40 (74.1)	1.27 (0.64-2.52), <i>P</i> = 0.490
CD68 TC/NM	20 (48.8)	0.73 (0.37-1.42), <i>P</i> = 0.357	26 (50.0)	0.64 (0.35-1.18), <i>P</i> = 0.154
CD80 NM	31 (73.8)	0.56 (0.26-1.17), <i>P</i> = 0.121	39 (75.0)	0.56 (0.28-1.11), <i>P</i> = 0.095
CD80 TC	30 (73.2)	1.13 (0.54-2.36), <i>P</i> = 0.744	39 (75.0)	0.75 (0.39-1.44), <i>P</i> = 0.392
CD80 TC/NM	20 (48.8)	1.21 (0.62-2.37), <i>P</i> = 0.574	24 (49.0)	0.92 (0.49-1.70), <i>P</i> = 0.784

Densities of macrophages (mm<sup>2</sup>) were converted into percentiles and then categorized into low (0-24 percentile) and high (25-100 percentile). Ratio of tumor center/NM was calculated by dividing the densities of macrophages in tumor center by their densities in NM. The median values of these ratios were used to classify the samples into 'high' and 'low' groups. Hazard

ratios show the relative risk compared with 1.00 for low groups.

**Supplementary Table 6 Associations of clinical and pathology variables in primary colorectal cancer and liver metastases with overall survival (univariable analysis) in stage I-III and stage IV colorectal cancer patients**

Variables	Group	Stage I-III		Stage IV	
		<i>n</i> (%)	HR (95%CI), <i>P</i> value	<i>n</i> (%)	HR (95%CI), <i>P</i> value
Gender	Male	29 (65.9)	1.00	34 (61.8)	1.00
	Female	15 (34.1)	1.55 (0.68-3.54), <i>P</i> = 0.30	21 (38.2)	1.55 (0.82-2.93), <i>P</i> = 0.18
Age	Under Median	19 (43.2)	1.00	30 (54.5)	1.00
	Above Median	25 (56.8)	0.78 (0.34-1.79), <i>P</i> = 0.51	25 (45.5)	0.61 (0.33-1.15), <i>P</i> = 0.13
Size of primary colorectal cancer	Under Median	22 (50.0)	1.00	27 (49.1)	1.00
	Above Median	22 (50.0)	1.21 (0.53-2.76), <i>P</i> = 0.66	28 (50.9)	0.76 (0.41-1.44), <i>P</i> = 0.40
	Median				
Grade of primary colorectal cancer	1	14 (31.8)	1.00	9 (19.1)	1.00
	2	26 (59.1)	0.84 (0.35-2.03), <i>P</i> = 0.70	32 (68.1)	1.48 (0.59-3.72), <i>P</i> = 0.41
	3	4 (9.1)	1.41 (0.30-6.73), <i>P</i> = 0.67	6 (12.8)	1.32 (0.39-4.54), <i>P</i> = 0.66
Sideness	Right	8 (18.2)	1.00	12 (21.8)	1.00
	Left	36 (81.8)	0.50 (0.19-1.31), <i>P</i> = 0.16	43 (78.2)	0.96 (0.45-2.02), <i>P</i> = 0.9
N grade	0	13 (29.5)	1.00	13 (23.6)	1.00
	1	16 (36.4)	0.93 (0.37-2.35), <i>P</i> = 0.88	22 (40.0)	1.22 (0.56-2.64), <i>P</i> = 0.62
	2	15 (34.1)	0.42 (0.14-1.30), <i>P</i> = 0.13	20 (36.4)	1.50 (0.68-3.35), <i>P</i> = 0.32
Median size of LM	Under Median	22 (50.0)	1.00	27 (49.1)	1.00
	Above Median	22 (50.0)	0.67 (0.30-1.52), <i>P</i> = 0.34	28 (50.9)	0.77 (0.42-1.42), <i>P</i> = 0.40
	Median				
Number of LM	1	25 (58.1)	1.00	25 (46.3)	1.00
	> 1	18 (41.9)	1.87 (0.83-4.18), <i>P</i> = 0.13	29 (53.7)	1.60 (0.84-3.07), <i>P</i> = 0.16

Grade of LM	1	18 (42.9)	1.00	21 (39.6)	1.00
	2	24 (57.1)	1.01 (0.45-2.31), <i>P</i> = 0.97	32 (60.4)	0.85 (0.44-1.65), <i>P</i> = 0.64
Margin of LM	R0	29 (69.0)	1.00	40 (76.9)	1.00
	R1	13 (31.0)	1.61 (0.70-3.71), <i>P</i> = 0.27	12 (23.1)	0.97 (0.46-2.05), <i>P</i> = 0.93
CHT regimen	Other	28 (63.6)	1.00	31 (56.4)	1.00
	FOLFOX16	16 (36.4)	0.36 (0.13-0.97), <i>P</i> = 0.04	24 (43.6)	1.38 (0.72-2.63), <i>P</i> = 0.33
Use of targeted therapy	No	30 (75.0)	1.00	29 (59.2)	1.00
	Yes	10 (25.0)	0.93 (0.36-2.40), <i>P</i> = 0.90	20 (40.8)	1.03 (0.51-2.09), <i>P</i> = 0.93

Median age: synchronous = 62, metachronous = 64; median size for primary tumor: synchronous = 4.3 cm, metachronous = 3.5 cm; median size of liver metastasis: synchronous = 2.0 cm, metachronous = 2.7 cm.

**Supplementary Table 7 Densities of CD163+ and CD80+ macrophages in NM associated with overall survival (multivariable analysis) in colorectal cancer patients**

Cell type and location		<i>n</i> (%)	HR (95%CI), <i>P</i> value
Stage I-III			
Model 1			
CD80 NM	Low	11 (26.2)	-
	High	31 (73.8)	0.17 (0.06-0.47), <i>P</i> = 0.001
N stage	0	13 (29.5)	-
	1	16 (36.4)	0.87 (0.28-2.72), <i>P</i> = 0.812
	2	20 (36.4)	0.28 (0.06-1.25), <i>P</i> = 0.094
Grade of primary tumor	1	14 (31.8)	-
	2	26 (59.1)	2.39 (0.67-8.60), <i>P</i> = 0.182
	3	4 (9.1)	2.28 (0.44-11.70), <i>P</i> = 0.323
Model 2			
CD80 NM	Low	11 (26.2)	-
	High	31 (73.8)	0.40 (0.15-1.06), <i>P</i> = 0.066
Regimen	Other	28 (63.6)	-
	FOLFOX	16 (36.4)	0.42 (0.13-1.36), <i>P</i> = 0.147
Targeted therapy	No	30 (75.0)	-

	Yes	10 (25.0)	0.97 (0.35-2.72), <i>P</i> = 0.953
Model 3			
CD80 NM	Low	11 (26.2)	-
	High	31 (73.8)	0.20 (0.06-0.62), <i>P</i> = 0.005
Number of LM	1	25 (58.1)	-
	>1	18 (41.9)	1.67 (0.70-3.98), <i>P</i> = 0.247
Size of LM	Under		
	med	22 (50.0)	-
	Above		1.25 (0.45-3.48), <i>P</i> = 0.669
Grade of LM	med	22 (50.0)	
	1	18 (42.9)	1.48 (0.58-3.75), <i>P</i> = 0.413
	2	24 (57.1)	
Stage IV			
Model 1			
CD163 NM	Low	14 (25.9)	-
	High	40 (74.1)	0.38 (0.15-0.99), <i>P</i> = 0.047
N stage	0	13 (23.6)	-
	1	22 (40.0)	0.80 (0.29-2.24), <i>P</i> =0.673
	2	20 (36.4)	1.15 (0.44-3.00), <i>P</i> = 0.769
Grade of primary tumor	1	9 (19.1)	-
	2	32 (68.1)	1.64 (0.50-5.45), <i>P</i> = 0.417
	3	6 (12.8)	1.31 (0.32-5.35), <i>P</i> = 0.710
Model 2			
CD163 NM	Low	14 (25.9)	-
	High	40 (74.1)	0.44 (0.20-0.96), <i>P</i> = 0.040

Regimen	Other	24 (43.6)	-
	FOLFOX	31 (56.4)	1.51 (0.72-3.17), <i>P</i> = 0.277
Targeted therapy Model 3	No	29 (59.2)	-
	Yes	20 (40.8)	0.81 (0.38-1.72), <i>P</i> = 0.575
CD163 NM	Low	14 (25.9)	-
	High	40 (74.1)	0.35 (0.16-0.78), <i>P</i> = 0.010
Number of LM	1	25 (46.3)	-
	>1	29 (53.7)	1.45 (0.71-2.92), <i>P</i> = 0.305
Size of LM	Under		
	med	27 (49.1)	-
	Above med	28 (50.9)	0.90 (0.47-1.75), <i>P</i> = 0.765
Grade of LM	1	21 (39.6)	-
	2	32 (60.4)	1.05 (0.50-2.20), <i>P</i> = 0.892

Model 1: adjusted for N stage and grade of primary tumor; model 2: adjusted for number, size and grade of liver metastases model; 3: adjusted for chemotherapy regimen (FOLFOX vs other and use of targeted therapy).

**Supplementary Table 8 Associations of clinicopathological variables with densities of macrophages in colorectal cancer patient stage I-III vs stage IV**

Cell type and location	Variables	NM stage I-III	I-TC stage I-III	NM stage IV	TC stage IV
CD80	Male	345(24-1143)	6(0-111)	279(9-1084)	3(0-115)
	Female	302(25-1001)	7.5(0-32)	114(3-750) <sup>a</sup>	5(0-61)
CD206	Male	328(58-1225)	114(12-767)	293(65-1926)	128(8-801)
	Female	549(65-1214)	183(18-489)	665(45-1306)	119(8-940)
CD68	Male	430(154-895)	119(2-786)	388(45-866)	97.5(8-574)
	Female	352(214-829)	124(3-1486)	296(41-928)	81(4-635)
CD163	Male	605(129-992)	378(102-1146)	550(142-1246)	395(107-1178)
	Female	720(377-935)	262(35-886)	551(2-1246)	302(31-849)
CD80	Age median	Above231.5(24-1143)	7.5(0-39)	231(4-814)	6.5(0-115)
	Age	Below343(25-863)	5(0-111)	138(3-1084)	2(0-61)

	median				
CD206	Age	Above361(58-1214)	111(12-767)	395(73-1306)	150(8-940)
	median				
	Age	Below342.5(64-1225)	196(12-748)	343(45-1926)	78(8-801)
	median				
CD68	Age	Above377(187-759)	97(12-786)	374(73-825)	136(9-423)
	median				
	Age	Below404(154-985)	199(2-1486)	366(41-928)	81(4-635)
	median				
CD163	Age	Above668.5(129-954)	334(35-813)	550(2-976)	356.5(103-849)
	median				
	Age	Below634(250-992)	385(62-1146)	551(142-1246)	386(31-1178)
	median				
CD80	Left-sided	268.5(24-863)	8(0-111)	200(4-1084)	2.5(0-61)
	Right- sided	551(34-1143)	4.5(0-20)	257(3-552)	7.5(1-115)
CD206	Left-sided	331(58-1109)	145(12-767)	357(45-1926)	117(8-940)
	Right- sided	772(199-1225)	89.5(36-484)	650.5(96-1076)	138.5(8-906)
CD68	Left-sided	394(171-895)	124(2-786)	365.5(41-928)	84(4-574)
	Right sided	352.5(154-829)	102(20-1486)	416(181-825)	187.5(18-635)
CD163	Left-sided	634(129-992)	367(35-1146)	543.5(2-1246)	328(31-780)
	Right sided	786.5(250-916)	362(102-700)	652.5(248-1246)	452(138-1178) <sup>a</sup>
CD80	pCRC size Above	346(70-751)	2(0-111)	185(3-550)	2(0-47)
	median	233(24-1143)	16(0-65) <sup>a</sup>	231(4-1084)	4(0-115)
	pCRC size Below				
	median				
CD206	pCRC size Above	250(64-598)	155(22-748)	299(65-1926)	129(8-940)
	median	549(58-1225) <sup>b</sup>	133(12-767)	395(45-1567)	110(8-801)
	pCRC size Below				
	median				
CD68	pCRC size Above	442(171-895)	166(19-1486)	377(45-928)	74(8-635)
	median	391(154-759)	105(2-786)	366(41-754)	99(4-574)
	pCRC size Below				
	median				

CD163	pCRC size Above	605(129-992)	397(102-1146)	623(2-1246)	347(92-849)
	median	681(250-954)	378(35-886)	529(143-976)	386(31-1178)
	pCRC size Below				
	median				
CD80	pCRC grade 1	218(24-1143)	9(0-111)	142(9-521)	2(0-19)
	pCRC grade 2	346(35-863)	6(0-65)	293(3-1084)	5(0-115)
	pCRC grade 3	274(25-432)	9(0-25)	49(21-214)	0(0-8)
CD206	pCRC grade 1	597(64-1225)	156(28-489)	458(85-1076)	137(8-906)
	pCRC grade 2	334(58-1214)	111(12-767)	375(45-1926)	110(8-940)
	pCRC grade 3	360(157-619)	134(18-209)	333(118-900)	130(14-472)
CD68	pCRC grade 1	367(154-895)	55(12-526)	381(267-928)	163(8-426)
	pCRC grade 2	405(171-829)	128(3-1486)	377(41-866)	84(4-635)
	pCRC grade 3	349(214-484)	121(2-454)	364(45-545)	55(15-314)
CD163	pCRC grade 1	703(250-992)	262(35-960)	625(143-939)	394(107-849)
	pCRC grade 2	617(129-954)	401(62-1146)	548(2-1246)	344(31-1178)
	pCRC grade 3	640(551-680)	473(228-528)	606(142-832)	416(92-630)
CD80	N stage 0	230(25-1143)	14(0-111)	162(3-814)	7.5(0-15)
	N stage 1	402(24-863)	8(0-65)	216(11-1084)	3(0-50)
	N stage 2	325(74-1001)	5(0-34)	192(12-750)	3(0-115)
	N stage 0	589(64-1225)	264(18-489)	650.5(102-1076)	137(40-906)
CD206	N stage 1	328(104-1214)	112(12-234)	423(73-1306)	132.5(8-940)
	N stage 2	367(58-1109)	142(22-767)	293(45-1926)	91(8-472)
CD68	N stage 0	442(154-895)	223(19-526)	312(181-545)	74(8-635)
	N stage 1	278(171-540)	50(2-255)	365(41-928)	87(4-574)
	N stage 2	479(194-829) <sup>a</sup>	208(11-1486)	383(45-866)	85(8-402)
	N stage 0	629(250-992)	260(62-960)	581(231-1246)	374(92-849)
CD163	N stage 1	671(129-846)	337(65-606)	526(2-976)	395(31-1178)
	N stage 2	675(265-954)	488(225-1146)	629(142-1246)	347(199-736)
CD80	LM size Above	354 (25-1143)	6 (0-44)	113 (3-1084)	2 (0-33)
	median	268 (24-1001)	9 (0-111)	310 (4-814)	4 (0-115)
	LM size Below				
	median				

CD206	LM size Above	334 (64-1109)	208 (18-748)	373 (73-1926)	134 (8-906)
	median	391 (58-1225)	92 (12-767)	371 (45-1567)	77 (8-940)
	LM size Below				
	median				
CD68	LM size Above	411 (187-895)	119 (3-1486)	373 (45-928)	84 (8-635)
	median	385 (154-671)	124 (2-786)	366 (41-754)	85 (4-426)
	LM size Below				
	median				
CD163	LM size Above	651 (129-992)	363 (35-960)	589 (142-1246)	394 (92-849)
	median	652 (250-954)	379 (62-1146)	531 (2-939)	342 (31-1178)
	LM size Below				
	median				
CD80	LM num >1	230 (24-1143)	19 (0-111)	218 (4-1084)	4 (0-47)
	LM num = 1	385 (25-1001)	4 (0-34)	113 (3-750)	3 (0-115)
CD206	LM num >1	330 (58-1225)	136 (12-748)	258 (65-1567)	77 (8-906)
	LM num =1	396 (104-1109)	134 (18-767)	545 (45-1926)	150 (14-940)
CD68	LM num >1	331 (154-895)	196 (21-1486)	366 (45-928)	87 (8-574)
	LM num =1	430 (214-631)	97 (2-786) <sup>a</sup>	376 (41-866)	85 (4-635)
CD163	LM num >1	677 (129-992)	449 (102-960)	548 (142-893)	385 (92-1178)
	LM num =1	639 (258-935)	341 (35-1146)	621 (2-1246)	320 (31-780)
CD80	LM grade 1	306 (24-1143)	7 (0-111)	170 (3-550)	5 (0-33)
	LM grade 2	348 (25-831)	7 (0-39)	241 (4-1084)	3 (0-115)
CD206	LM grade 1	334 (64-1225)	156 (12-748)	324 (85-1567)	77 (8-906)
	LM grade 2	356 (58-1109)	113 (12-459)	484 (45-1926)	150 (16-940)
CD68	LM grade 1	368 (154-895)	88 (12-526)	363 (45-928)	134 (8-635)
	LM grade 2	402 (171-829)	124 (2-1486)	374 (41-866)	79 (4-574)
CD163	LM grade 1	722 (129-992)	334 (35-960)	548 (142-1246)	386 (202-1178)
	LM grade 2	604 (265-954)	356 (62-1146)	612 (2-1246)	344 (31-780)

---

Median age: synchronous = 62, metachronous = 64; median size for primary tumor: synchronous = 4.3 cm, metachronous = 3.5 cm; median size of liver metastasis: synchronous = 2.0 cm, metachronous = 2.7 cm. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01.